Table 1.
Demographic and other baseline characteristics
| Variable | Genexol-PM (n=105) | Genexol (n=107) | p-value |
|---|---|---|---|
| Age (yr) | 49.0 (28.0-72.0) | 52.0 (25.0-78.0) | 0.02 |
| Menstruation status | |||
| Premenopausal | 61 (58.1) | 49 (45.8) | 0.10 |
| Postmenopausal | 44 (41.9) | 58 (54.2) | |
| ECOG status | |||
| 0 | 47 (44.8) | 31 (29.0) | 0.02 |
| 1 | 53 (50.5) | 68 (63.6) | |
| 2 | 5 (4.8) | 8 (7.5) | |
| DFI (yr) | 2.2 (0.2-8.7) | 3.0 (0.2-9.1) | 0.34 |
| No. target lesions | |||
| < 3 | 90 (85.7) | 94 (87.9) | 0.65 |
| ≥ 3 | 15 (14.3) | 13 (12.2) | |
| Visceral metastasis | |||
| Yes | 71 (67.6) | 65 (60.8) | 0.30 |
| No | 34 (32.4) | 42 (39.3) | |
| ER or PgR status | |||
| Positive | 75 (71.4) | 82 (76.6) | 0.63 |
| Negative | 28 (26.7) | 24 (22.4) | |
| Unknown | 2 (1.9) | 1 (0.9) | |
| De novo stage IV breast cancer | |||
| Yes | 71 (67.6) | 74 (69.2) | 0.81 |
| No | 34 (32.4) | 33 (30.8) | |
| Previous chemotherapya) | |||
| Yes | 16 (15.2) | 14 (13.1) | 0.70 |
| No | 89 (84.8) | 93 (86.9) |
Values are presented as median (range) or number (%). ECOG, Eastern Cooperative Oncology Group; DFI, disease-free interval; ER, estrogen receptor; PgR, progesterone receptor.
a)
Systemic cytotoxic chemotherapy for metastatic disease.